The effects of a 6-week intervention with Limosilactobacillus reuteri ATCC PTA 6475 alone and in combination with L. reuteri DSM 17938 on gut barrier function, immune markers, and symptoms in patients with IBS-D—An exploratory RCT
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0312464 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Julia König und 6 weiteren Autor:innen. Beteiligte Einrichtung: Nutrition-Gut-Brain Interactions Research Centre, Faculty of Health and Medicine, School of Medical Sciences, Örebro University, Örebro, Sweden. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Limosilactobacillus reuteri, Probiotics, Biomarkers. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Knowledge Foundation, Sweden.
Abstract (Originalsprache)
Background
An increased intestinal permeability is a common feature in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D). Probiotics have shown to improve IBS symptoms and might also affect intestinal barrier function.
Aim
The aim of this study was to investigate the effects of a 6-week intervention with Limosilactobacillus reuteri ATCC PTA 6475 alone (single strain) or in combination with Limosilactobacillus reuteri DSM 17938 (dual strain) on gut barrier function, immune markers, and symptoms in IBS-D patients (ClinicalTrials.gov registration number: NCT03986476).
Methods
65 IBS-D patients were randomised into three groups (placebo, single strain, dual strain). Small and large intestinal permeability were assessed using a multi-sugar urinary recovery test. Blood, saliva, faecal samples, and several symptom scales were collected before, and after three and six weeks of intervention.
Results
Small and large intestinal permeability as well as other markers of gut barrier function were not significantly affected by the probiotic interventions. Serum IL-6 levels showed a tendency to be reduced in the single strain group (descriptive p = 0.052). In addition, high-sensitivity C-reactive protein was significantly reduced in the dual strain group (p = 0.041). The participants in both treatment groups reported less gastrointestinal symptoms after three weeks, but this reached significance only in the dual strain group (total score: p = 0.032, pain subscore: p = 0.028). After six weeks, none of the assessed symptoms were significantly different from the placebo.
Conclusion
The probiotic compounds investigated in this study did not seem to affect IBS-D patients’ gut barrier function, but showed potential anti-inflammatory and symptom-improving properties, which need to be confirmed in larger study cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Nutrition-Gut-Brain Interactions Research Centre, Faculty of Health and Medicine, School of Medical Sciences, Örebro University, Örebro, Sweden.
- BioGaia AB, Eslöv, Sweden.
- BioGaia AB, Stockholm, Sweden.
ORCID-Profile: Julia König, María Fernanda Roca Rubio, Julia Rode
Förderung
- The Knowledge Foundation, Sweden
Zitieren
APA
König, J., Roca Rubio, M. F., Forsgård, R. A., Rode, J., Axelsson, J., Grompone, G., & Brummer, R. J. (2024). The effects of a 6-week intervention with Limosilactobacillus reuteri ATCC PTA 6475 alone and in combination with L. reuteri DSM 17938 on gut barrier function, immune markers, and symptoms in patients with IBS-D—An exploratory RCT. PLOS ONE. https://doi.org/10.1371/journal.pone.0312464
Vancouver
König J, Roca Rubio MF, Forsgård RA, Rode J, Axelsson J, Grompone G, et al. The effects of a 6-week intervention with Limosilactobacillus reuteri ATCC PTA 6475 alone and in combination with L. reuteri DSM 17938 on gut barrier function, immune markers, and symptoms in patients with IBS-D—An exploratory RCT. PLOS ONE. 2024. doi:10.1371/journal.pone.0312464
BibTeX
@article{Knig2024,
author = {König, Julia and Roca Rubio, María Fernanda and Forsgård, Richard A and Rode, Julia and Axelsson, Jakob and Grompone, Gianfranco and Brummer, Robert J},
title = {The effects of a 6-week intervention with Limosilactobacillus reuteri ATCC PTA 6475 alone and in combination with L. reuteri DSM 17938 on gut barrier function, immune markers, and symptoms in patients with IBS-D—An exploratory RCT},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0312464}
}
EUVIMED